Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02029638 · ClinicalTrials.gov registry record · Phase 2
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02029638 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 4 participants.
The verdict
NCT02029638, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the ability of bone marrow transplantation (BMT) and high-dose post-transplantation cyclophosphamide (PT/Cy) to induce renal allograft tolerance and thus enable discontinuation of immunosuppressive therapy in haploidentical living related donor renal transplant recipients.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- RADIATION Total Body Irradiation
- BIOLOGICAL anti-thymocyte globulin
- DRUG acetaminophen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-01-07 |
| Est. Completion | 2017-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02029638
The ClinicalTrials.gov registry entry for NCT02029638 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02029638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02029638 about?
NCT02029638 is a clinical study titled "BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance". The primary objective of this study is to assess the ability of bone marrow transplantation (BMT) and high-dose post-transplantation cyclophosphamide (PT/Cy) to induce renal allograft tolerance and thus enable discontinuation of immunosuppressive therapy in haploidentical living related donor renal ...
What is the current status of trial NCT02029638?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2014-01-07. Estimated completion is 2017-09-06.
What interventions are being tested in trial NCT02029638?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Total Body Irradiation (RADIATION), anti-thymocyte globulin (BIOLOGICAL), acetaminophen (DRUG).
Who is sponsoring clinical trial NCT02029638?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.